Altheos Sees $20M In Series A

South San Francisco-based Altheos announced today that it has raised $20M in a Series A funding. The firm, which is licensing a set of compounds from Japanese firm Asahi Kasei Pharma for the topical treatment of glaucoma, said the funding was led by Bay City Capital, and also included Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. As part of the funding, Lester Kaplan and Rob Hopfner of Bay City Capital both join the board, as does Peter Bisgaard of Novo A/S and Wende Hutton of Canaan Partners. More information »